International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

The Intelligent Cancer Clinic: AI Applications in Modern Oncology

Dr. Sneha Kapoor[1], Dr. Arvind Menon[2], Mrs. Kavita Sharma[3], Dr. Sameer Joshi[4], Mr. Nitin Rao[5]

[1]Professor Department of Clinical Pharmacy, Northern Biomedical University, Chandigarh, India sneha.kapoor1978@gmail.com
[2]Assistant Professor Department of Pharmaceutics, Northern Biomedical University, Chandigarh, India arvindm.84@gmail.com
[3]Associate Professor Department of Pharmaceutical Analysis, Northern Biomedical University, Chandigarh, India kavitasharma22@gmail.com
[4]Professor Department of Pharmacology, Northern Biomedical University, Chandigarh, India sameer.j07@gmail.com
[5]Assistant Professor Department of Pharmacognosy, Northern Biomedical University, Chandigarh, India nitinrao1989@gmail.com

ABSTRACT

Artificial intelligence (AI) has emerged as one of the most transformative technologies in modern oncology, fundamentally changing how cancer is detected, diagnosed, treated, and monitored. Rapid advances in machine learning, deep learning, computer vision, natural language processing, generative AI, and foundation models have enabled healthcare systems to process enormous volumes of clinical, radiological, pathological, genomic, and molecular information with unprecedented speed and accuracy. Unlike conventional decision-support systems that analyze isolated datasets, intelligent oncology platforms integrate multimodal patient information to provide comprehensive clinical insights across the entire continuum of cancer care. AI-powered tools are increasingly supporting early cancer detection, automated medical imaging interpretation, digital pathology, molecular profiling, precision medicine, treatment planning, immunotherapy prediction, and real-time clinical decision support. Furthermore, the integration of electronic health records, wearable devices, cloud computing, and predictive analytics has enabled the development of continuously learning oncology ecosystems capable of adapting to evolving patient conditions. Although these technologies demonstrate tremendous promise, important challenges remain regarding algorithmic bias, explainability, regulatory approval, interoperability, cybersecurity, ethical governance, and equitable implementation. This review provides a comprehensive overview of artificial intelligence applications within the modern cancer clinic, highlighting technological foundations, current clinical applications, and emerging innovations that are shaping the future of precision oncology.[1]

Keywords: *Artificial intelligence, Oncology, Precision medicine, Machine learning, Deep learning, Digital pathology, Radiology, Clinical decision support, Cancer diagnostics, Intelligent healthcare.*

Article History
Received: 10 December 2025; **Accepted:** 18 December 2025; **Published:** 28 December 2025

Citation
Kapoor S., (2025). The Intelligent Cancer Clinic: AI Applications in Modern Oncology. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 1(5), 18-25.*
DOI: https://doi.org/10.65477/2026.v.1i.5.03

1. Introduction

Cancer remains one of the leading causes of mortality worldwide despite remarkable progress in molecular biology, targeted therapies, immunotherapy, and precision medicine. The biological complexity of cancer extends far beyond genetic mutations, involving intricate interactions among tumor cells, immune responses, stromal components, metabolic pathways, and environmental influences. Consequently, patients with similar histological diagnoses frequently demonstrate markedly different responses to identical therapeutic regimens, emphasizing the need for individualized clinical decision-making.[2]

Modern oncology generates enormous quantities of heterogeneous biomedical data through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, laboratory investigations, wearable monitoring devices, and electronic health records. Although each source provides valuable clinical information, integrating these diverse datasets exceeds the capabilities of conventional analytical approaches and traditional clinical workflows.[3]

Artificial intelligence has emerged as a powerful solution capable of transforming complex biomedical information into clinically meaningful knowledge. AI systems can recognize subtle imaging abnormalities, predict molecular alterations, estimate treatment response, stratify patient risk, automate administrative workflows, and continuously learn from expanding clinical datasets. These capabilities are enabling the development of the intelligent cancer clinic, where AI augments clinical expertise throughout diagnosis, treatment planning, and long-term patient management.[4]

Rather than replacing oncologists, AI functions as an intelligent clinical partner that enhances diagnostic precision, improves workflow efficiency, reduces variability, and supports evidence-based decision-making. As computational technologies continue to mature, AI is becoming an integral component of multidisciplinary oncology practice, creating new opportunities for truly personalized cancer care.[5]

2. Evolution of Artificial Intelligence in Oncology

The application of artificial intelligence in oncology has evolved considerably over the past several decades. Early computer-assisted diagnostic systems relied primarily on rule-based algorithms that used predefined clinical criteria to support physician decision-making. While useful for simple tasks, these systems lacked adaptability and were unable to learn from newly acquired clinical information.[6]

The emergence of machine learning introduced data-driven predictive modeling capable of identifying complex relationships between clinical variables and patient outcomes. Algorithms such as decision trees, random forests, support vector machines, and gradient boosting demonstrated promising performance in predicting recurrence, treatment response, and survival across multiple cancer types.[7]

Subsequent advances in deep learning dramatically expanded AI capabilities by enabling automated extraction of high-dimensional features directly from medical images and pathological specimens. Convolutional neural networks revolutionized image interpretation, while recurrent neural networks improved temporal analysis of longitudinal clinical data.[8]

More recently, transformer architectures, multimodal foundation models, and generative AI have enabled comprehensive analysis of imaging, pathology, genomics, laboratory investigations, and clinical documentation within unified computational frameworks. These developments have laid the foundation for intelligent oncology ecosystems capable of supporting virtually every stage of cancer care.[9]

3. Foundations of the Intelligent Cancer Clinic

The intelligent cancer clinic represents an integrated healthcare environment in which artificial intelligence continuously assists clinicians through automated data analysis, predictive modeling, personalized recommendations, and workflow optimization. Rather than functioning as isolated software applications, modern AI systems interact with multiple hospital information systems to provide coordinated clinical support.[10]

At the core of this ecosystem lies multimodal data integration. Clinical information is collected from radiological imaging, pathology laboratories, molecular diagnostics, genomic sequencing, laboratory reports, pharmacy systems, electronic health records, and patient-reported outcomes. AI algorithms harmonize these heterogeneous datasets into unified patient representations that facilitate comprehensive clinical assessment.

Cloud computing and high-performance computational infrastructure enable continuous processing of large-scale biomedical information while maintaining rapid clinical response times. Interactive dashboards present AI-generated predictions, risk estimates, treatment recommendations, and longitudinal disease trajectories in formats that complement physician expertise rather than replace it.[11]

This integrated approach supports multidisciplinary collaboration among medical oncologists, radiation oncologists, surgeons, radiologists, pathologists, molecular biologists, pharmacists, and nursing teams, ensuring that individualized patient management benefits from the collective expertise of the entire oncology workforce.

4. Machine Learning Technologies Driving Modern Oncology

Machine learning forms the computational backbone of many contemporary oncology applications. Unlike traditional statistical models, machine learning algorithms identify complex nonlinear relationships within high-dimensional biomedical datasets, allowing prediction of clinically relevant outcomes that may not be apparent through conventional analysis.[12]

Supervised learning models are widely used for cancer diagnosis, recurrence prediction, toxicity estimation, and survival analysis. These algorithms learn predictive relationships from labeled datasets, enabling accurate classification and risk stratification across diverse malignancies.

Unsupervised learning techniques identify hidden imaging phenotypes, and molecular characteristics. Such approaches have contributed significantly to the discovery of novel cancer subtypes and improved understanding of tumor heterogeneity.

Semi-supervised and self-supervised learning methods further enhance performance by utilizing large quantities of unlabeled medical data, reducing dependence on expensive manual annotation while improving generalizability across different healthcare settings.[13]

As machine learning algorithms continue to evolve, they are increasingly incorporated into routine oncology practice through clinical decision-support platforms that assist physicians in selecting individualized diagnostic and therapeutic strategies.

5. Deep Learning in Cancer Diagnosis

Deep learning has fundamentally transformed cancer diagnosis by enabling automated analysis of complex biomedical images with remarkable accuracy. Deep neural networks automatically extract hierarchical features from imaging data without requiring manual feature engineering, allowing recognition of subtle disease characteristics that may be difficult for human observers to identify consistently.[14]

Convolutional neural networks have become particularly important in radiology, pathology, dermatology, ophthalmology, and endoscopy. These models detect tumors, classify lesion types, segment anatomical structures, estimate tumor volume, and monitor disease progression across multiple imaging modalities.

Deep learning algorithms also improve consistency by reducing observer variability among clinicians. Automated detection systems provide rapid second opinions that may reduce diagnostic errors while improving workflow efficiency in busy oncology centers.

Continuous learning enables these models to improve over time as additional clinical data become available, supporting increasingly accurate diagnostic performance across diverse patient populations.[15]

6. Artificial Intelligence in Medical Imaging

Medical imaging represents one of the most mature applications of AI in oncology. Computed tomography, magnetic resonance imaging, positron emission tomography, mammography, ultrasound, and hybrid imaging generate enormous volumes of diagnostic information that can be efficiently analyzed using artificial intelligence.[16]

AI-powered image analysis assists radiologists through automated tumor detection, organ segmentation, lesion characterization, response assessment, and disease staging. Quantitative imaging biomarkers extracted biological subgroups by clustering genomic profiles, through radiomics provide objective measures of tumor heterogeneity, vascularity, morphology, and texture that complement conventional visual interpretation.

Longitudinal image analysis enables continuous monitoring of treatment response by comparing sequential examinations over time. AI systems identify subtle imaging changes that may indicate therapeutic effectiveness or early disease progression before they become clinically apparent.

These capabilities improve diagnostic precision while reducing interpretation time, allowing radiologists to focus on complex clinical decision-making rather than repetitive image review.

7. Digital Pathology and Computational Histopathology

Digital pathology has become a cornerstone of intelligent oncology by converting conventional glass slides into high-resolution whole-slide images suitable for computational analysis. AI-powered pathology systems analyze millions of microscopic tissue regions simultaneously, providing quantitative assessment of tumor architecture, cellular morphology, stromal composition, immune infiltration, and vascular remodeling.[17]

Transformer-based pathology models identify subtle histological features associated with tumor subtype, aggressiveness, metastatic potential, and therapeutic response. These computational systems improve diagnostic reproducibility while supporting more objective pathological assessment.

One of the most significant advances involves prediction of molecular biomarkers directly from histopathological images. Deep learning algorithms have demonstrated the ability to infer clinically relevant genetic alterations, including EGFR mutations, KRAS mutations, HER2 amplification, microsatellite instability, and PD-L1 expression using routine tissue morphology alone.[18]

Computational pathology also enables detailed characterization of the tumor microenvironment, providing valuable information regarding immune-cell distribution, fibrosis, angiogenesis, and stromal interactions that influence treatment response and patient prognosis.

8. Radiomics and Radiogenomics

Radiomics extends the value of medical imaging by extracting hundreds of quantitative imaging features describing tumor morphology, texture, intensity, shape, and spatial organization. Rather than relying solely on qualitative visual interpretation, radiomics transforms routine clinical imaging into rich quantitative datasets suitable for advanced predictive modeling.[19]

Radiogenomics further integrates these imaging biomarkers with genomic and molecular information, significant genetic alterations. AI algorithms identify relationships between imaging phenotypes and underlying molecular pathways, supporting precision oncology without requiring repeated tissue biopsies.

These technologies facilitate longitudinal assessment of tumor evolution by allowing repeated molecular inference throughout disease progression using standard imaging studies. This approach is particularly valuable in metastatic disease, where repeated tissue sampling may be clinically challenging or unsafe.[20]

The combination of radiomics and radiogenomics enables more comprehensive characterization of tumor biology while supporting individualized treatment planning and response prediction.

9. AI in Genomic Medicine and Precision Oncology

Genomic medicine has become central to precision oncology, yet interpreting the enormous complexity of genomic sequencing data remains a significant clinical challenge. Artificial intelligence facilitates rapid analysis of genomic variants, gene-expression profiles, mutational signatures, and molecular pathways associated with cancer development and therapeutic response.[21]

Machine learning algorithms identify actionable mutations, predict drug sensitivity, estimate resistance mechanisms, and classify tumors according to their molecular characteristics. AI also integrates genomic information with clinical, pathological, and imaging data to generate comprehensive patient-specific therapeutic recommendations.

Advanced computational models support interpretation of next-generation sequencing results by prioritizing clinically relevant variants while reducing interpretation time. These capabilities accelerate molecular tumor board discussions and improve implementation of personalized treatment strategies.

As genomic databases continue to expand, AI will play an increasingly important role in translating complex molecular information into clinically actionable knowledge, further advancing the goals of precision oncology.[22]

10. Artificial Intelligence in Treatment Planning

One of the greatest contributions of artificial intelligence to modern oncology is its ability to support individualized treatment planning. Conventional treatment decisions often rely on population-based clinical guidelines; however, AI enables physicians to incorporate patient-specific clinical, pathological, radiological, and molecular information into personalized therapeutic recommendations.[23]

enabling non-invasive prediction of clinically

Machine learning models estimate treatment response, recurrence risk, progression-free survival, and overall survival under different therapeutic strategies. By analyzing thousands of similar patient profiles, AI assists clinicians in selecting the most appropriate chemotherapy regimens, targeted therapies, immunotherapies, radiation schedules, or multimodal treatment combinations.

Importantly, these systems function as clinical decision-support tools rather than autonomous decision-makers. Final therapeutic choices remain under physician supervision, ensuring that AI complements clinical expertise while improving precision and consistency in patient care.

11. Artificial Intelligence in Radiation Oncology

Radiation therapy remains a cornerstone of cancer treatment, yet conventional planning requires extensive manual contouring, dose optimization, and repeated quality assurance procedures. Artificial intelligence has significantly streamlined these workflows by automating target delineation, organ segmentation, treatment planning, and adaptive dose optimization.[24]

Deep learning algorithms accurately identify tumors and surrounding normal tissues from computed tomography and magnetic resonance imaging, reducing planning time while improving reproducibility. AI also supports adaptive radiotherapy by continuously evaluating anatomical changes during treatment, allowing radiation plans to be modified according to tumor shrinkage or normal tissue displacement.

These intelligent planning systems improve treatment precision, minimize radiation exposure to healthy organs, and enhance overall treatment efficiency within busy oncology departments.

12. Artificial Intelligence in Immuno-Oncology

Immunotherapy has transformed cancer treatment by enabling the immune system to recognize and eliminate malignant cells. Nevertheless, only a proportion of patients achieve durable responses, making prediction of immunotherapy benefit a major clinical priority.

Artificial intelligence integrates genomic alterations, tumor mutational burden, PD-L1 expression, immune-cell infiltration, digital pathology, radiological imaging, circulating biomarkers, and clinical characteristics to estimate the likelihood of response to immune checkpoint inhibitors.[25]

Advanced computational models also characterize the tumor microenvironment by quantifying lymphocyte distribution, stromal architecture, inflammatory signaling pathways, and immune-cell interactions. These analyses improve patient selection while supporting development of individualized immunotherapeutic strategies.

As immunotherapy continues to expand across multiple cancer types, AI-driven predictive models are expected to further optimize treatment selection while minimizing unnecessary toxicity and healthcare costs.

13. Clinical Decision Support Systems

The intelligent cancer clinic increasingly depends upon AI-powered clinical decision-support systems capable of synthesizing enormous quantities of biomedical information into clinically meaningful recommendations. These systems integrate laboratory investigations, radiological findings, pathology reports, genomic analyses, medication histories, treatment responses, and electronic health records into unified clinical dashboards.[26]

Rather than overwhelming clinicians with fragmented information, AI organizes patient data into actionable summaries that highlight important diagnostic findings, estimate individualized risks, recommend evidence-based treatment options, and identify patients requiring urgent intervention.

Natural language processing further enhances workflow efficiency by automatically extracting relevant clinical information from physician notes, pathology reports, discharge summaries, and multidisciplinary meeting documentation. These capabilities reduce administrative burden while allowing clinicians to devote more time to direct patient care.

14. Generative AI and Foundation Models in Oncology

Recent advances in generative artificial intelligence and large foundation models represent a major milestone in computational oncology. Unlike conventional AI systems designed for single tasks, foundation models learn generalized biomedical representations from enormous multimodal datasets and can subsequently be adapted to numerous oncology applications.[27]

Generative AI supports automated clinical documentation, literature summarization, patient education, molecular design, drug discovery, synthetic data generation, and conversational clinical assistance. These technologies accelerate knowledge translation while reducing repetitive administrative tasks within oncology practice.

Multimodal foundation models capable of simultaneously analyzing radiology, pathology, genomics, laboratory data, and clinical narratives may eventually provide comprehensive patient-level reasoning across the entire cancer care continuum. Although careful clinical validation remains essential, these systems have enormous potential to improve efficiency and accessibility in future oncology services.

15. Explainable Artificial Intelligence and Ethical Considerations

Clinical adoption of artificial intelligence depends not only upon predictive accuracy but also on transparency, fairness, and trust. Explainable artificial intelligence (XAI) seeks to make AI-generated predictions understandable to clinicians by identifying the factors that most strongly influence model decisions.[28]

Techniques such as saliency maps, attention visualization, SHAP (Shapley Additive Explanations), feature attribution analysis, and counterfactual explanations enable physicians to interpret AI recommendations within appropriate clinical contexts. Explainability improves confidence in AI-assisted decision-making while facilitating multidisciplinary communication.

Despite these advances, important ethical challenges remain. Algorithmic bias arising from non-representative datasets may reduce model performance among underrepresented populations. Additional concerns include patient privacy, informed consent, cybersecurity, accountability, regulatory oversight, and equitable access to advanced AI technologies. Addressing these issues is essential for responsible integration of AI into routine oncology practice.

16. Future Directions of the Intelligent Cancer Clinic

The future intelligent cancer clinic will likely integrate artificial intelligence with robotics, wearable technologies, cloud computing, digital health platforms, liquid biopsy, molecular diagnostics, and continuously learning healthcare systems.[29]

Wearable sensors will enable continuous monitoring of physiological parameters, treatment-related toxicities, and patient-reported outcomes beyond the hospital environment. AI algorithms will analyze these longitudinal data streams to identify early signs of disease progression, treatment complications, or functional decline, enabling timely clinical intervention.

Future oncology ecosystems are expected to incorporate multimodal foundation models capable of continuously learning from diverse patient populations while supporting real-time multidisciplinary collaboration. International data-sharing initiatives, standardized clinical protocols, federated learning, and secure cloud infrastructure will further improve model robustness and generalizability across healthcare systems.

17. Discussion

Artificial intelligence has rapidly evolved from an experimental technology into an essential component of modern oncology. Across the cancer care continuum, AI enhances diagnostic accuracy, improves workflow efficiency, facilitates precision medicine, supports therapeutic planning, predicts treatment response, and assists long-term patient management. Integration of radiology, pathology, genomics, molecular biology, and electronic health records enables comprehensive patient-centered decision-making that would be difficult to achieve using conventional analytical methods alone.

Despite remarkable technological progress, several barriers continue to limit widespread implementation. Data heterogeneity, limited interoperability, computational resource requirements, regulatory uncertainty, cybersecurity concerns, algorithmic bias, and clinician acceptance remain significant challenges.

Successful implementation will require rigorous prospective validation, transparent governance frameworks, multidisciplinary collaboration, and continuous physician oversight to ensure safe, equitable, and clinically effective deployment of AI technologies.[30]

18. Conclusion

Artificial intelligence is fundamentally transforming the modern cancer clinic by enabling data-driven, personalized, and evidence-based oncology care. Through applications in medical imaging, digital pathology, genomics, radiation oncology, immunotherapy, clinical decision support, and precision medicine, AI enhances both diagnostic and therapeutic decision-making while improving operational efficiency.

Future advances in foundation models, multimodal learning, explainable AI, federated learning, and generative artificial intelligence are expected to further strengthen the role of intelligent clinical systems in oncology. Although technical, ethical, regulatory, and implementation challenges remain, continued interdisciplinary collaboration among clinicians, computer scientists, engineers, and healthcare policymakers will accelerate responsible clinical adoption.

Rather than replacing healthcare professionals, artificial intelligence will serve as a powerful clinical partner, augmenting human expertise and supporting a more predictive, preventive, personalized, and patient-centered model of cancer care. As these technologies continue to mature, the intelligent cancer clinic is poised to become a defining feature of next-generation precision oncology, ultimately improving outcomes, optimizing resource utilization, and enhancing the quality of care for patients worldwide.

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Wei, L. et al. (2023) ‘Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration’, British Journal of Radiology, 96(1150), Article 20230211.
3. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
4. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
5. Chakraborty, S. et al. (2022) ‘Multi-omics Integration in Oncology: From Data to Clinical Insights’, Cancer Cell, 40(8), pp. 805-823.
6. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
7. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
8. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

9. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
11. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
12. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
13. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
14. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
15. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
10. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21
16. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
17. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33
18. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
19. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
20. Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.
21. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
22. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.

23. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
24. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
25. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
26. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
27. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
28. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
29. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
30. Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.